home / stock / stsa / stsa quote
Last: | $ |
---|---|
Change Percent: | 4.02% |
Open: | $26.92 |
Close: | $28.18 |
High: | $29.07 |
Low: | $26.0107 |
Volume: | 24,266 |
Last Trade Date Time: | 02/12/2020 04:43:31 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $26.92 | $28.18 | $29.07 | $26.0107 | 24,266 | 02-12-2020 |
$ | $28.83 | $27.09 | $29.4679 | $26.80 | 58,020 | 02-11-2020 |
$ | $33.48 | $29.60 | $33.48 | $28.52 | 78,674 | 02-10-2020 |
$ | $23.37 | $30.69 | $30.99 | $23.37 | 90,909 | 02-07-2020 |
$ | $23.90 | $23.21 | $24.33 | $21.83 | 110,731 | 02-06-2020 |
$ | $24.90 | $23.71 | $25.035 | $23.51 | 46,605 | 02-05-2020 |
$ | $25.87 | $24.58 | $26.38 | $24.58 | 67,927 | 02-04-2020 |
$ | $24.90 | $25.75 | $26.33 | $24.42 | 68,421 | 02-03-2020 |
$ | $25.77 | $24.72 | $26.33 | $24.11 | 33,866 | 01-31-2020 |
$ | $29.00 | $25.59 | $29.2045 | $25.04 | 61,917 | 01-30-2020 |
$ | $25.92 | $29.03 | $29.89 | $25.92 | 116,218 | 01-29-2020 |
$ | $19.69 | $25.47 | $25.92 | $19.69 | 68,857 | 01-28-2020 |
$ | $19.27 | $19.60 | $19.66 | $18.94 | 38,010 | 01-27-2020 |
$ | $20.05 | $19.67 | $20.75 | $19.60 | 38,291 | 01-24-2020 |
$ | $19.54 | $19.98 | $20.1748 | $19.4381 | 44,536 | 01-23-2020 |
$ | $19.50 | $20.05 | $20.915 | $19.40 | 62,806 | 01-22-2020 |
$ | $19.48 | $19.90 | $20.06 | $19.00 | 48,842 | 01-21-2020 |
$ | $18.90 | $19.58 | $19.78 | $17.71 | 87,090 | 01-20-2020 |
$ | $18.90 | $19.58 | $19.78 | $17.71 | 87,090 | 01-17-2020 |
$ | $17.21 | $18.98 | $19.30 | $17.00 | 98,287 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Satsuma Pharmaceuticals Inc. Company Name:
STSA Stock Symbol:
NYSE Market:
DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. , a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic produc...
January 2024 PDUFA date expected If approved, STS101 would become the only DHE product evaluated in a randomized, placebo-controlled trial (the SUMMIT trial) against modern outcome measures recommended by both the U.S. Food and Drug Administration (FDA) and International Headache Society ...
NEW YORK, NY / ACCESSWIRE / May 1, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hoth Therapeutics, Inc. (NASDAQ:HOTH)'s...